{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:48:21Z","timestamp":1790434101854,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1007593"],"award-info":[{"award-number":["1007593"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","award":["FT110100752"],"award-info":[{"award-number":["FT110100752"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00406-019-00978-2","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T05:57:01Z","timestamp":1547877421000},"page":"17-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":169,"title":["A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5222-5637","authenticated-orcid":false,"given":"Nadia","family":"Solowij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3440-6792","authenticated-orcid":false,"given":"Samantha","family":"Broyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1921","authenticated-orcid":false,"given":"Lisa-marie","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-9143","authenticated-orcid":false,"given":"Hendrika","family":"van Hell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Martelozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuna","family":"Rueb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-600X","authenticated-orcid":false,"given":"Juanita","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-7238","authenticated-orcid":false,"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-2529","authenticated-orcid":false,"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-0199","authenticated-orcid":false,"given":"Jennifer","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-0519","authenticated-orcid":false,"given":"Robin","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-2953","authenticated-orcid":false,"given":"Alison","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4169-8519","authenticated-orcid":false,"given":"Patricia T.","family":"Michie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-9136","authenticated-orcid":false,"given":"Rodney","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,19]]},"reference":[{"key":"978_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","volume":"370","author":"TH Moore","year":"2007","unstructured":"Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319\u2013328","journal-title":"Lancet"},{"key":"978_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and \u22069-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737\u2013753","journal-title":"Br J Pharmacol"},{"key":"978_CR3","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805","journal-title":"Br J Pharmacol"},{"key":"978_CR4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"DC D\u2019Souza","year":"2004","unstructured":"D\u2019Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-T, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558\u20131572","journal-title":"Neuropsychopharmacology"},{"key":"978_CR5","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1017\/S0033291709005522","volume":"39","author":"PD Morrison","year":"2009","unstructured":"Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM (2009) The acute effects of synthetic intravenous \u22069-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39:1607\u20131616","journal-title":"Psychol Med"},{"key":"978_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","volume":"79","author":"SJ Broyd","year":"2016","unstructured":"Broyd SJ, van Hell HH, Beale C, Y\u00fccel M, Solowij N (2016) Acute and chronic effects of cannabinoids on human cognition: a systematic review. Biol Psychiatry 79:557\u2013567","journal-title":"Biol Psychiatry"},{"key":"978_CR7","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.biopsych.2015.11.013","volume":"79","author":"V Lorenzetti","year":"2016","unstructured":"Lorenzetti V, Solowij N, Y\u00fccel M (2016) The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol Psychiatry 79:e17\u2013e31","journal-title":"Biol Psychiatry"},{"key":"978_CR8","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1038\/tp.2015.201","volume":"6","author":"M Y\u00fccel","year":"2016","unstructured":"Y\u00fccel M, Lorenzetti V, Suo C, Zalesky A, Fornito A, Takagi MJ, Lubman DI, Solowij N (2016) Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry 6:e710","journal-title":"Transl Psychiatry"},{"key":"978_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","volume":"2","author":"M Di Forti","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case\u2013control study. The Lancet Psychiatry 2:233\u2013238","journal-title":"The Lancet Psychiatry"},{"key":"978_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764\u2013774","journal-title":"Neuropsychopharmacology"},{"key":"978_CR11","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94","journal-title":"Transl Psychiatry"},{"key":"978_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","volume":"72","author":"AL Osborne","year":"2017","unstructured":"Osborne AL, Solowij N, Weston-Green K (2017) A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev 72:310\u2013324","journal-title":"Neurosci Biobehav Rev"},{"key":"978_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225\u2013231","journal-title":"Am J Psychiatry"},{"key":"978_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","volume":"79","author":"MA ElSohly","year":"2016","unstructured":"ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995\u20132014): analysis of current data in the United States. Biol Psychiatry 79:613\u2013619","journal-title":"Biol Psychiatry"},{"key":"978_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2215-0366(17)30075-5","volume":"4","author":"A Englund","year":"2017","unstructured":"Englund A, Freeman TP, Murray RM, McGuire P (2017) Can we make cannabis safer? The Lancet Psychiatry 4:643\u2013648","journal-title":"The Lancet Psychiatry"},{"key":"978_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/bph.12400","volume":"170","author":"R Mechoulam","year":"2013","unstructured":"Mechoulam R, Parker L (2013) Towards a better cannabis drug. Br J Pharmacol 170:1363\u20131364","journal-title":"Br J Pharmacol"},{"key":"978_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","volume":"197","author":"CJA Morgan","year":"2010","unstructured":"Morgan CJA, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197:285\u2013290","journal-title":"Br J Psychiatry"},{"key":"978_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","volume":"192","author":"CJA Morgan","year":"2008","unstructured":"Morgan CJA, Curran HV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306\u2013307","journal-title":"Br J Psychiatry"},{"key":"978_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","volume":"130","author":"CD Schubart","year":"2011","unstructured":"Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216\u2013221","journal-title":"Schizophr Res"},{"key":"978_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19\u201327","journal-title":"J Psychopharmacol"},{"key":"978_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245\u2013250","journal-title":"Psychopharmacology"},{"key":"978_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pbb.2009.04.010","volume":"93","author":"DT Malone","year":"2009","unstructured":"Malone DT, Jongejan D, Taylor DA (2009) Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 93:91\u201396","journal-title":"Pharmacol Biochem Behav"},{"key":"978_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/can.2017.0034","volume":"2","author":"M Murphy","year":"2017","unstructured":"Murphy M, Mills S, Winstone J, Leishman E, Wager-Miller J, Bradshaw H, Mackie K (2017) Chronic adolescent \u2206(9)-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis Cannabinoid Res 2:235\u2013246","journal-title":"Cannabis Cannabinoid Res"},{"key":"978_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/can.2017.0047","volume":"3","author":"C Beale","year":"2018","unstructured":"Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH, Y\u00fccel M, Solowij N (2018) Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. Cannabis Cannabinoid Res 3:94\u2013107","journal-title":"Cannabis Cannabinoid Res"},{"key":"978_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C, Prick J-A, Greenwood L-M, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Y\u00fccel M (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3:21\u201334","journal-title":"Cannabis Cannabinoid Res"},{"key":"978_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00428793","volume":"33","author":"IG Karniol","year":"1973","unstructured":"Karniol IG, Carlini EA (1973) Pharmacological interaction between cannabidiol and \u03b49-tetrahydrocannabinol. Psychopharmacologia 33:53\u201370","journal-title":"Psychopharmacologia"},{"key":"978_CR27","first-page":"12","volume":"269","author":"AW Zuardi","year":"1984","unstructured":"Zuardi AW, Teixeira NA, Karniol IC (1984) Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 269:12\u201319","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"978_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00213-006-0356-9","volume":"186","author":"SA Varvel","year":"2006","unstructured":"Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, Martin BR (2006) Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186:226\u2013234","journal-title":"Psychopharmacology"},{"key":"978_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.brainres.2007.09.090","volume":"1188","author":"K Hayakawa","year":"2008","unstructured":"Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M (2008) Cannabidiol potentiates pharmacological effects of \u22069-tetrahydrocannabinol via CB1 receptor-dependent mechanism. Brain Res 1188:157\u2013164","journal-title":"Brain Res"},{"key":"978_CR30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bph.12199","volume":"170","author":"MJ Wright Jr","year":"2013","unstructured":"Wright MJ Jr, Vandewater SA, Taffe MA (2013) Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol. Br J Pharmacol 170:1365\u20131373","journal-title":"Br J Pharmacol"},{"key":"978_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00213-011-2342-0","volume":"218","author":"C Klein","year":"2011","unstructured":"Klein C, Karanges E, Spiro A et al (2011) Cannabidiol potentiates \u22069-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218:443\u2013457","journal-title":"Psychopharmacology"},{"key":"978_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bph.13333","volume":"173","author":"SM Todd","year":"2016","unstructured":"Todd SM, Arnold JC (2016) Neural correlates of interactions between cannabidiol and \u2206(9) -tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol 173:53\u201365","journal-title":"Br J Pharmacol"},{"key":"978_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.euroneuro.2016.12.004","volume":"27","author":"SM Todd","year":"2017","unstructured":"Todd SM, Zhou C, Clarke DJ, Chohan TW, Bahceci D, Arnold JC (2017) Interactions between cannabidiol and \u22069-THC following acute and repeated dosing: rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. Eur Neuropsychopharmacol 27:132\u2013145","journal-title":"Eur Neuropsychopharmacol"},{"key":"978_CR34","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/npp.2010.58","volume":"35","author":"CJ Morgan","year":"2010","unstructured":"Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010) Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35:1879\u20131885","journal-title":"Neuropsychopharmacology"},{"key":"978_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","volume":"25","author":"C Hindocha","year":"2015","unstructured":"Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV (2015) Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25:325\u2013334","journal-title":"Eur Neuropsychopharmacol"},{"key":"978_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","volume":"64","author":"R Mechoulam","year":"2013","unstructured":"Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21\u201347","journal-title":"Annu Rev Psychol"},{"key":"978_CR37","doi-asserted-by":"publisher","first-page":"13096","DOI":"10.1523\/JNEUROSCI.1297-14.2014","volume":"34","author":"B Draycott","year":"2014","unstructured":"Draycott B, Loureiro M, Ahmad T, Tan H, Zunder J, Laviolette SR (2014) Cannabinoid transmission in the prefrontal cortex bi-phasically controls emotional memory formation via functional interactions with the ventral tegmental area. J Neurosci 34:13096\u201313109","journal-title":"J Neurosci"},{"key":"978_CR38","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/npp.2014.329","volume":"40","author":"M Loureiro","year":"2015","unstructured":"Loureiro M, Renard J, Zunder J, Laviolette SR (2015) Hippocampal cannabinoid transmission modulates dopamine neuron activity: impact on rewarding memory formation and social interaction. Neuropsychopharmacology 40:1436\u20131447","journal-title":"Neuropsychopharmacology"},{"key":"978_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF02244012","volume":"100","author":"FS Guimar\u00e3es","year":"1990","unstructured":"Guimar\u00e3es FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558\u2013559","journal-title":"Psychopharmacology"},{"key":"978_CR40","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.pnpbp.2009.08.017","volume":"33","author":"AC Campos","year":"2009","unstructured":"Campos AC, Guimar\u00e3es FS (2009) Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 33:1517\u20131521","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"978_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"AW Zuardi","year":"2017","unstructured":"Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimar\u00e3es FS, Crippa JAS (2017) Inverted U-shaped dose\u2013response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 8:259\u2013259","journal-title":"Front Pharmacol"},{"key":"978_CR42","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2017-0015","author":"IM Linares","year":"2018","unstructured":"Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimar\u00e3es FS, Crippa JA (2018) Cannabidiol presents an inverted U-shaped dose\u2013response curve in a simulated public speaking test. Braz J Psychiatry. \n                    https:\/\/doi.org\/10.1590\/1516-4446-2017-0015","journal-title":"Braz J Psychiatry"},{"key":"978_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1248\/bpb.19.1109","volume":"19","author":"K Watanabe","year":"1996","unstructured":"Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109\u20131111","journal-title":"Biol Pharm Bull"},{"key":"978_CR44","first-page":"960","volume":"292","author":"F Rakhshan","year":"2000","unstructured":"Rakhshan F, Day TA, Blakely RD, Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292:960\u2013967","journal-title":"J Pharmacol Exp Ther"},{"key":"978_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br J Pharmacol 153:199\u2013215","journal-title":"Br J Pharmacol"},{"key":"978_CR46","first-page":"141","volume":"16","author":"AW Zuardi","year":"1983","unstructured":"Zuardi AW, Karniol IG (1983) Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res 16:141\u2013146","journal-title":"Braz J Med Biol Res"},{"key":"978_CR47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00213-011-2495-x","volume":"219","author":"AW Zuardi","year":"2012","unstructured":"Zuardi AW, Hallak JEC, Crippa JAS (2012) Interaction between cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology 219:247\u2013249","journal-title":"Psychopharmacology"},{"key":"978_CR48","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.2174\/138161212802884726","volume":"18","author":"JC Arnold","year":"2012","unstructured":"Arnold JC, Boucher AA, Karl T (2012) The Yin and Yang of cannabis-induced psychosis: the actions of \u22069-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr Pharm Des 18:5113\u20135130","journal-title":"Curr Pharm Des"},{"key":"978_CR49","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neubiorev.2016.09.007","volume":"76","author":"MM Silveira","year":"2017","unstructured":"Silveira MM, Arnold JC, Laviolette SR, Hillard CJ, Celorrio M, Aymerich MS, Adams WK (2017) Seeing through the smoke: human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. Neurosci Biobehav Rev 76:380\u2013395","journal-title":"Neurosci Biobehav Rev"},{"key":"978_CR50","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.euroneuro.2017.10.037","volume":"27","author":"T Hlo\u017eek","year":"2017","unstructured":"Hlo\u017eek T, Uttl L, Kade\u0159\u00e1bek L, Bal\u00edkov\u00e1 M, Lhotkov\u00e1 E, Horsley RR, Nov\u00e1kov\u00e1 P, \u0160\u00edchov\u00e1 K, \u0160tefkov\u00e1 K, Tyl\u0161 F, Kucha\u0159 M, P\u00e1len\u00ed\u010dek T (2017) Pharmacokinetic and behavioural profile of THC, CBD, and THC + CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol 27:1223\u20131237","journal-title":"Eur Neuropsychopharmacol"},{"key":"978_CR51","first-page":"825","volume":"23","author":"LM Bornheim","year":"1995","unstructured":"Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ (1995) Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23:825\u2013831","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"978_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1476-5381.1972.tb08092.x","volume":"45","author":"G Jones","year":"1972","unstructured":"Jones G, Pertwee RG (1972) A metabolic interaction in vivo between cannabidiol and \u22061-tetrahydrocannabinol. Br J Pharmacol 45(2):375\u2013377","journal-title":"Br J Pharmacol"},{"key":"978_CR53","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327\u2013360","journal-title":"Clin Pharmacokinet"},{"key":"978_CR54","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/jps.20574","volume":"95","author":"A Hazekamp","year":"2006","unstructured":"Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R (2006) Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 95:1308\u20131317","journal-title":"J Pharm Sci"},{"key":"978_CR55","doi-asserted-by":"publisher","first-page":"e184838","DOI":"10.1001\/jamanetworkopen.2018.4838","volume":"1","author":"N Solowij","year":"2018","unstructured":"Solowij N (2018) Peering through the haze of smoked vs vaporized cannabis\u2014to vape or not to vape? JAMA Netw Open 1:e184838","journal-title":"JAMA Netw Open"},{"key":"978_CR56","doi-asserted-by":"publisher","first-page":"e184841","DOI":"10.1001\/jamanetworkopen.2018.4841","volume":"1","author":"TR Spindle","year":"2018","unstructured":"Spindle TR, Cone EJ, Schlienz NJ et al (2018) Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open 1:e184841","journal-title":"JAMA Netw Open"},{"key":"978_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41398-018-0191-x","volume":"8","author":"CJA Morgan","year":"2018","unstructured":"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181","journal-title":"Transl Psychiatry"},{"key":"978_CR58","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1556-4029.2007.00603.x","volume":"53","author":"DJ Potter","year":"2008","unstructured":"Potter DJ, Clark P, Brown MB (2008) Potency of \u22069-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90\u201394","journal-title":"J Forensic Sci"},{"key":"978_CR59","doi-asserted-by":"publisher","first-page":"e70052","DOI":"10.1371\/journal.pone.0070052","volume":"8","author":"W Swift","year":"2013","unstructured":"Swift W, Wong A, Li KM, Arnold JC, McGregor IS (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 8:e70052","journal-title":"PLoS One"},{"key":"978_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/2050-6511-15-58","volume":"15","author":"N Solowij","year":"2014","unstructured":"Solowij N, Broyd SJ, van Hell HH, Hazekamp A (2014) A protocol for the delivery of cannabidiol (CBD) and combined CBD and \u22069-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol 15:58","journal-title":"BMC Pharmacol Toxicol"},{"key":"978_CR61","first-page":"242","volume":"114","author":"T Demirakca","year":"2011","unstructured":"Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, Mann K, Hermann D (2011) Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 114:242\u2013245","journal-title":"Drug Alcohol Depend"},{"key":"978_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring alcohol consumption: psychosocial and biological methods","author":"L Sobell","year":"1992","unstructured":"Sobell L, Sobell M (1992) Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ (eds) Measuring alcohol consumption: psychosocial and biological methods. Humana Press, Totowa, pp\u00a041\u201372"},{"key":"978_CR63","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","volume":"88","author":"JB Saunders","year":"1993","unstructured":"Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88:791\u2013804","journal-title":"Addiction"},{"issue":"Suppl 20","key":"978_CR64","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22\u201333","journal-title":"J Clin Psychiatry"},{"key":"978_CR65","volume-title":"Manual for the State-Trait Anxiety Inventory","author":"CD Spielberger","year":"1983","unstructured":"Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto"},{"key":"978_CR66","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward C, Mendelson M (1961) Beck Depression Inventory (BDI). Arch Gen Psychiatry 4:561\u2013571","journal-title":"Arch Gen Psychiatry"},{"key":"978_CR67","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1017\/S0033291701005141","volume":"32","author":"N Stefanis","year":"2002","unstructured":"Stefanis N, Hanssen M, Smirnis N, Avramopoulos D, Evdokimidis I, Stefanis C, Verdoux H, Van Os J (2002) Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med 32:347\u2013358","journal-title":"Psychol Med"},{"key":"978_CR68","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/schbul\/17.4.555","volume":"17","author":"A Raine","year":"1991","unstructured":"Raine A (1991) The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 17:555","journal-title":"Schizophr Bull"},{"key":"978_CR69","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1360-0443.1995.9056072.x","volume":"90","author":"M Gossop","year":"1995","unstructured":"Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607\u2013614","journal-title":"Addiction"},{"key":"978_CR70","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000092678","volume":"39","author":"EJ Barkus","year":"2006","unstructured":"Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39:175\u2013178","journal-title":"Psychopathology"},{"key":"978_CR71","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/add.13082","volume":"110","author":"RJ Niesink","year":"2015","unstructured":"Niesink RJ, Rigter S, Koeter MW, Brunt TM (2015) Potency trends of \u22069-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in The Netherlands: 2005\u201315. Addiction 110:1941\u20131950","journal-title":"Addiction"},{"key":"978_CR72","first-page":"13","volume":"12","author":"P Galettis","year":"2016","unstructured":"Galettis P (2016) Development of a simple LCMSMS method for THC and metabolites in plasma. Asia Pac J Clin Oncol 12:13\u201334","journal-title":"Asia Pac J Clin Oncol"},{"key":"978_CR73","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11:125\u2013136","journal-title":"J Trauma Stress"},{"key":"978_CR74","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00000542-199801000-00015","volume":"88","author":"TA Bowdle","year":"1998","unstructured":"Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesia 88:82\u201388","journal-title":"Anesthesia"},{"key":"978_CR75","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0269881108089581","volume":"22","author":"L Zuurman","year":"2008","unstructured":"Zuurman L, Roy C, Schoemaker RC et al (2008) Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 22:707\u2013716","journal-title":"J Psychopharmacol"},{"key":"978_CR76","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.schres.2008.02.020","volume":"103","author":"OJ Mason","year":"2008","unstructured":"Mason OJ, Morgan CJM, Stefanovic A, Curran HV (2008) The Psychotomimetic States Inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 103:138\u2013142","journal-title":"Schizophr Res"},{"key":"978_CR77","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"978_CR78","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","volume":"66","author":"E Russo","year":"2006","unstructured":"Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234\u2013246","journal-title":"Med Hypotheses"},{"key":"978_CR79","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pnpbp.2010.11.002","volume":"35","author":"JEC Hallak","year":"2011","unstructured":"Hallak JEC, Dursun SM, Bosi DC et al (2011) The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 35:198\u2013202","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"978_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14440","author":"M Tham","year":"2018","unstructured":"Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB (2018) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. \n                    https:\/\/doi.org\/10.1111\/bph.14440","journal-title":"Br J Pharmacol"},{"key":"978_CR81","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1124\/mol.118.111864","volume":"94","author":"A Straiker","year":"2018","unstructured":"Straiker A, Dvorakova M, Zimmowitch A, Mackie K (2018) Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons. Mol Pharmacol 94:743\u2013748","journal-title":"Mol Pharmacol"},{"key":"978_CR82","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","volume":"372","author":"M Kathmann","year":"2006","unstructured":"Kathmann M, Flau K, Redmer A, Tr\u00e4nkle C, Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372:354\u2013361","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"978_CR83","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","volume":"9","author":"JA Crippa","year":"2018","unstructured":"Crippa JA, Guimar\u00e3es FS, Campos AC, Zuardi AW (2018) Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol 9:2009","journal-title":"Front Immunol"},{"key":"978_CR84","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/mol.112.080879","volume":"83","author":"GL Baillie","year":"2013","unstructured":"Baillie GL, Horswill JG, Anavi-Goffer S et al (2013) CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 83:322\u2013338","journal-title":"Mol Pharmacol"},{"key":"978_CR85","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1096\/fj.14-263053","volume":"29","author":"RS Priestley","year":"2015","unstructured":"Priestley RS, Nickolls SA, Alexander SPH, Kendall DA (2015) A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. FASEB J 29:1446\u20131455","journal-title":"FASEB J"},{"key":"978_CR86","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (2018) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32:1053\u20131067","journal-title":"CNS Drugs"},{"key":"978_CR87","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/cpt1976193300","volume":"19","author":"WS Dalton","year":"1976","unstructured":"Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976) Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19:300\u2013309","journal-title":"Clin Pharmacol Ther"},{"key":"978_CR88","unstructured":"Fleming A (2018) Cannabis health products are everywhere\u2014but do they live up to the hype? The Guardian. \n                    https:\/\/www.theguardian.com\/lifeandstyle\/2018\/oct\/15\/cannabis-health-products-live-up-to-hype-cannabidiol-cbd\n                    \n                  . Accessed 15 Oct 2018"},{"key":"978_CR89","first-page":"5","volume":"5","author":"N Solowij","year":"2012","unstructured":"Solowij N (2012) Vulnerability markers in the association between cannabis and schizophrenia: a randomised controlled trial of acute cannabinoid administration. Curr Controll Trials 5:5","journal-title":"Curr Controll Trials"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-019-00978-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-00978-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-00978-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T12:50:08Z","timestamp":1589633408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-019-00978-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,19]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1007\/s00406-019-00978-2","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,19]]},"assertion":[{"value":"13 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the University of Wollongong and Illawarra Shoalhaven Local Health District Health and Medical Human Research Ethics Committee and registered as a clinical trial (ISRCTN24109245 []). Participants provided written informed consent prior to participating in the study and at the start of each drug session.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}